Advancing Psychedelics Research for Treating Addiction (R61/R33 Basic Experimental Study with Humans Required)

Funding Agency:
National Institutes of Health

The purpose of this n otice of f unding o pportunity (NOFO) is to encourage clinical research that will advance understanding of how substance use disorder (SUD) relevant cognitive, emotional, and social processes are modulated by Psychedelics. Applications are expected to be exploratory and developmental in nature. As such, these studies may involve considerable risk of failure but may lead to a breakthrough in a particular area that could have a major impact on SUD research involving psychedelics.

This NOFO uses a R61/R33 Phased Innovation award activity code to support applications that propose Basic Experimental Studies Involving Humans (BESH) that meet both the definition of basic research and the NIH definition of a clinical trial. 

Types of studies that should submit under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

Mechanistic studies designed to understand a behavioral or biological process, the pathophysiology of a disease, or the mechanism of action of an intervention should submit under the companion NOFO - Advancing Psychedelics Research for Treating Addiction (R61/R33--Clinical Trial Required) RFA-DA-24-024.

For projects that do not require a phased research approach, applicants are encouraged to apply under a different funding mechanism (e.g., PA-20-184 Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)."

This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. 

Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.




  • Letter of Intent Due Date(s): October 2, 2023

  • Application Due Date: November 02, 2023

RFA-DA-24-029 Expiration Date November 03, 2023

Agency Website

Amount Description


For the R61 planning phase, the combined budget for direct costs for up to two years may not exceed $700,000. For the R33 phase, budgets may not exceed $500,000 per year and need to reflect the actual needs of the proposed project. 

Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

November 2, 2023